Details

Autor(en) / Beteiligte

• HOOPMANN, M.
• SACHSE, K.
• VALTER, M.M.
• BECKER, M.
• NEUMANN, R.
• ORTMANN, M.
• GÖHRING, U.-J.
• THOMAS, A.
• MALLMANN, P.
• SCHÖNDORF, T.

Titel

Serological and immunohistochemical HER-2/neu statuses do not correlate and lack prognostic value for ovarian cancer patients

Ist Teil von

• European journal of cancer care, 2010-11, Vol.19 (6), p.809-815

Ort / Verlag

Oxford, UK: Blackwell Publishing Ltd

Erscheinungsjahr

2010

Quelle

Wiley-Blackwell Full Collection

Beschreibungen/Notizen

• HOOPMANN M., SACHSE K., VALTER M.M., BECKER M., NEUMANN R., ORTMANN M., GÖHRING U.‐J., THOMAS A., MALLMANN P. & SCHÖNDORF T. (2010) European Journal of Cancer Care
Serological and immunohistochemical HER‐2/neu statuses do not correlate and lack prognostic value for ovarian cancer patients The serodiagnostics of extracellular domain (ECD) HER‐2/neu has turned into an evidenced‐based tumour marker for HER‐2/neu‐positive breast cancer patients. This study investigated the clinical relevance of immunohistochemical and serum HER‐2/neu in 44 patients with advanced ovarian cancer. The Hercept‐Test® from DAKO Diagnostics was used to analyse immunohistochemical HER‐2/neu expression. The HER‐2/neu ECD in serum was determined quantitatively by Bayer Immuno 1™ Immunoanalyser. The HER‐2/neu serum values were correlated to the clinical course of disease and to established prognostic factors, i.e. progression‐free and overall survival. Some 23% of patients (n= 11) expressed HER‐2/neu serum levels higher than 15 ng/mL, whereas only 7.7% (n= 2) of the patients examined by immunohistochemistry showed a HER‐2/neu overexpression of the tissue. None of them revealed an overexpression of HER‐2/neu ECD by serodiagnostics. HER‐2/neu overexpression did not correlate significantly to any of the analysed prognostic factors. According to progression‐free and overall survival, there was no significant difference between serologically HER‐2/neu‐positive or negative patients. For ovarian cancer patients, neither high HER‐2/neu serum levels, nor immunohistochemically determined HER‐2/neu positivity, appear to predict the course of disease. This study shows a lack of association between the immunohistochemical HER‐2/neu status and the serum level of solute extracelluar HER‐2/neu domain.